Paper Details

  1. Home
  2. Paper Details

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Author: , AlamJohn, BengtssonLeif, BourlièreMarc, BronowickiJean-Pierre, DusheikoGeoffrey, FerenciPeter, ForestierNicole, GeorgeShelley, GharakhanianShahin, GoeserTobias, HézodeChristophe, KauffmanRobert S, KiefferTara, KwongAnn, McNairLindsay, PawlotskyJean-Michel, PolStanislas, ZeuzemStefan

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study discusses the potential role of telaprevir, an HCV serine protease inhibitor, in treating hepatitis C virus (HCV) genotype 1 infection. Current treatment with peginterferon alfa and ribavirin has a 40-50% sustained virologic response rate.
Paper Details　
Original Abstract of the Article :
In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of 40 to 50%. Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa0807650

データ提供：米国国立医学図書館（NLM）

Telaprevir: A New Hope for Hepatitis C Treatment?

Hepatitis C virus (HCV) infection is a significant global health challenge. This research explores the potential of [telaprevir], an [HCV serine protease inhibitor], as a valuable addition to the treatment regimen for chronic HCV infection. The study investigated the effectiveness of telaprevir in combination with [peginterferon alfa and ribavirin] in patients with [chronic HCV infection genotype 1]. The results show that [telaprevir could be of value in HCV treatment]. While the study emphasizes the need for further research, it highlights the promising potential of telaprevir in addressing this critical health concern.

The Promise of Telaprevir

The study suggests that [telaprevir could be a valuable addition] to the treatment regimen for chronic HCV infection. This is promising news, as current treatment options for HCV infection have limited efficacy and can have significant side effects. The study underscores the need for further research to fully explore the potential of telaprevir in the treatment of HCV infection.

Navigating the Landscape of Hepatitis C Treatment

Hepatitis C is a serious health concern, and treatment options can be complex and challenging. This research suggests that telaprevir might offer a new path to effective treatment. However, it's important to consult with your doctor to discuss the risks and benefits of all treatment options, just like a traveler in a desert might seek guidance from a local guide before embarking on a challenging journey.

Dr.Camel's Conclusion

The study's findings suggest that telaprevir could be a promising addition to the treatment regimen for chronic HCV infection. However, further research is needed to fully explore its efficacy and determine its optimal application. Remember, just as the desert holds secrets waiting to be uncovered, the field of medicine is constantly seeking new solutions to improve patient health.

Date :
  1. Date Completed 2009-05-07
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

19403903

DOI: Digital Object Identifier

10.1056/NEJMoa0807650

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.